We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy or Sell Centene Stock Before Q3 Earnings Report?
Read MoreHide Full Article
Centene Corporation (CNC - Free Report) is set to report third-quarter 2024 results on Oct. 25, 2024, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $1.39 per shareon revenues of $37.9 billion.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
The third-quarter earnings estimate has witnessed downward revisions over the past 60 days. The bottom-line projection indicates a year-over-year plunge of 30.5%. Also, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decline of 0.4%.
Image Source: Zacks Investment Research
Centene beat the consensus estimate in three of the last four quarters and missed once, with the average surprise being 9.6%.
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
CNC has an Earnings ESP of -1.69% and a Zacks Rank #4 (Sell).
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Centene's third-quarter performance is expected to have benefited from enhanced contributions from its Commercial business. The positives are expected to have been amplified by the launch of new programs across different states and growth in memberships. However, a decline in premiums and rising medical costs are likely to have offset the positives.
Both the Zacks Consensus Estimate and our model estimate for the company’s total commercial memberships indicate a more than 17% year-over-year increase, primarily due to growth in the commercial marketplace. Both the consensus estimate and our model estimate for Medicare PDP memberships signal nearly 47% growth from the year-ago quarter.
The Zacks Consensus Estimate for overall membership growth is pegged at 1.6%, whereas our model estimate indicates a 1.8% rise. This is expected to have been partially offset by a decline in Medicaid memberships. Both the consensus estimate and our model estimate for the company’s Medicaid memberships indicate around a 14% decline from a year ago. This is likely to have affected premiums. The Zacks Consensus Estimate for the company’s premiums indicates a 0.2% fall from the prior-year reported level, whereas our model predicts a 0.4% decline.
The consensus estimate for service revenues indicates a more than 24% fall from the year-ago quarter’s $1.1 billion. Moreover, with seniors continuing the resumption of elective procedures following the pause during the pandemic, CNC’s medical costs are expected to have remained elevated in the third quarter. This is expected to have resulted in a year-over-year decline in profit margins. The Zacks Consensus Estimate for the total health benefits ratio is pegged at 88.64%, up from 87% in the year-ago period, meaning a reduced portion remaining in hand after paying claims.
These factors are likely to have positioned the company for a year-over-year decline, making an earnings beat uncertain. Nevertheless, the falling cost of services and some other expenses in the quarter under review are likely to have aided the bottom line. Our estimate for the total operating expenses suggests a 0.2% year-over-year decline. Also, the Zacks Consensus Estimate for the company’s investment and other income indicates more than 97% year-over-year growth from $214 million. These are likely to have provided some respite.
CNC’s Price Performance & Valuation
Centene's stock has declined 17.7% year to date, underperforming the industry’s growth of 2.1%. Some of its peers like Humana Inc. (HUM - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) have plunged 42.7% and 21.4%, respectively, during this time. All these stocks have lagged the S&P 500 significantly, which has rallied 22.7% during the same period.
CNC’s YTD Price Performance
Image Source: Zacks Investment Research
Now, let’s look at the value Centene offers investors at current levels.
The company’s valuation looks cheaper compared with the industry average. Currently, CNC is trading at 8.45X forward 12 months earnings, below its five-year median of 11.71X and the industry’s average of 15.89X, indicating investors’ lack of confidence in the stock.
Image Source: Zacks Investment Research
Assessing Centene’s Prospects
Centene’s diversified portfolio and expected growth in the commercial marketplace business position it for long-term growth. Its partnerships and acquisitions are targeted at expanding the company’s markets and increasing its memberships. The company also doesn’t shy away from getting rid of operations with lower profitability.
However, challenges such as high debt levels and rising medical costs are concerns. Its debt burden can affect its inorganic growth strategy. Rising medical costs continue to catch health insurers off guard, as they seem to lack a full understanding of the situation yet. Increasing costs, higher medical care ratio and tighter federal reimbursement rules will likely haunt companies like CNC. Investors should closely monitor these factors.
Final Words
While CNC’s long-term outlook remains promising, it might not be the right time to buy just yet. New investors seeking immediate gains should exercise patience for a more favorable entry point. Rushing into the market now may restrict potential profits. For current shareholders, it might be prudent to lock in profits now. The stock appears to have limited short-term growth potential.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Buy or Sell Centene Stock Before Q3 Earnings Report?
Centene Corporation (CNC - Free Report) is set to report third-quarter 2024 results on Oct. 25, 2024, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $1.39 per shareon revenues of $37.9 billion.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
The third-quarter earnings estimate has witnessed downward revisions over the past 60 days. The bottom-line projection indicates a year-over-year plunge of 30.5%. Also, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decline of 0.4%.
Centene beat the consensus estimate in three of the last four quarters and missed once, with the average surprise being 9.6%.
Centene Corporation Price and EPS Surprise
Centene Corporation price-eps-surprise | Centene Corporation Quote
Q3 Earnings Whispers for CNC
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
CNC has an Earnings ESP of -1.69% and a Zacks Rank #4 (Sell).
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
What’s Shaping CNC’s Q3 Results?
Centene's third-quarter performance is expected to have benefited from enhanced contributions from its Commercial business. The positives are expected to have been amplified by the launch of new programs across different states and growth in memberships. However, a decline in premiums and rising medical costs are likely to have offset the positives.
Both the Zacks Consensus Estimate and our model estimate for the company’s total commercial memberships indicate a more than 17% year-over-year increase, primarily due to growth in the commercial marketplace. Both the consensus estimate and our model estimate for Medicare PDP memberships signal nearly 47% growth from the year-ago quarter.
The Zacks Consensus Estimate for overall membership growth is pegged at 1.6%, whereas our model estimate indicates a 1.8% rise. This is expected to have been partially offset by a decline in Medicaid memberships. Both the consensus estimate and our model estimate for the company’s Medicaid memberships indicate around a 14% decline from a year ago. This is likely to have affected premiums. The Zacks Consensus Estimate for the company’s premiums indicates a 0.2% fall from the prior-year reported level, whereas our model predicts a 0.4% decline.
The consensus estimate for service revenues indicates a more than 24% fall from the year-ago quarter’s $1.1 billion. Moreover, with seniors continuing the resumption of elective procedures following the pause during the pandemic, CNC’s medical costs are expected to have remained elevated in the third quarter. This is expected to have resulted in a year-over-year decline in profit margins. The Zacks Consensus Estimate for the total health benefits ratio is pegged at 88.64%, up from 87% in the year-ago period, meaning a reduced portion remaining in hand after paying claims.
These factors are likely to have positioned the company for a year-over-year decline, making an earnings beat uncertain. Nevertheless, the falling cost of services and some other expenses in the quarter under review are likely to have aided the bottom line. Our estimate for the total operating expenses suggests a 0.2% year-over-year decline. Also, the Zacks Consensus Estimate for the company’s investment and other income indicates more than 97% year-over-year growth from $214 million. These are likely to have provided some respite.
CNC’s Price Performance & Valuation
Centene's stock has declined 17.7% year to date, underperforming the industry’s growth of 2.1%. Some of its peers like Humana Inc. (HUM - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) have plunged 42.7% and 21.4%, respectively, during this time. All these stocks have lagged the S&P 500 significantly, which has rallied 22.7% during the same period.
CNC’s YTD Price Performance
Now, let’s look at the value Centene offers investors at current levels.
The company’s valuation looks cheaper compared with the industry average. Currently, CNC is trading at 8.45X forward 12 months earnings, below its five-year median of 11.71X and the industry’s average of 15.89X, indicating investors’ lack of confidence in the stock.
Assessing Centene’s Prospects
Centene’s diversified portfolio and expected growth in the commercial marketplace business position it for long-term growth. Its partnerships and acquisitions are targeted at expanding the company’s markets and increasing its memberships. The company also doesn’t shy away from getting rid of operations with lower profitability.
However, challenges such as high debt levels and rising medical costs are concerns. Its debt burden can affect its inorganic growth strategy. Rising medical costs continue to catch health insurers off guard, as they seem to lack a full understanding of the situation yet. Increasing costs, higher medical care ratio and tighter federal reimbursement rules will likely haunt companies like CNC. Investors should closely monitor these factors.
Final Words
While CNC’s long-term outlook remains promising, it might not be the right time to buy just yet. New investors seeking immediate gains should exercise patience for a more favorable entry point. Rushing into the market now may restrict potential profits. For current shareholders, it might be prudent to lock in profits now. The stock appears to have limited short-term growth potential.